Clinical Trial Update: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating reinduction with Nadofaragene firadenovec in bladder cancer patients with CIS ± high-grade Ta/T1 and no complete response to the firs…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ

Drugs mentioned

• Nadofaragene firadenovec (nadofaragene firadenovec)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Bladder Cancer, Ta/T1 | Phase 4 | Status: WITHDRAWN